SELANK

While both Selank and benzodiazepines reduce anxiety through the GABAergic system, they work differently. Benzodiazepines directly bind to specific benzodiazepine sites on GABA-A receptors, causing sedation, memory impairment, and physical dependence. Selank allosterically modulates GABA-A receptors without these side effects. Clinical trials show comparable anxiolytic efficacy but Selank also has antiasthenic (anti-fatigue) and psychostimulatory effects, plus cognitive enhancement rather than impairment.

A key randomized controlled trial studied 62 patients with generalized anxiety disorder (GAD) and neurasthenia, comparing intranasal Selank (30 patients) to oral medazepam (32 patients) for 14 days. Both showed similar anxiolytic effects on Hamilton, Zung, and CGI scales, but Selank also demonstrated antiasthenic and psychostimulatory properties. Importantly, Selank increased enkephalin activity in blood serum, correlating with anxiety reduction. No sedation, dependence, or withdrawal was observed.

Selank was approved by the Russian Federation Ministry of Health in 2009 and is available by prescription in Russia and Ukraine as a 0.15% intranasal solution for the treatment of generalized anxiety disorder. It is not approved by the FDA in the United States or by regulatory agencies in most other countries, where it remains classified as a research compound.

In clinical trials, Selank is administered intranasally as a 0.15% solution. The standard protocol is 2 drops (75 mcg per drop) in each nostril, 3 times daily for 14 days (total ~1,350 mcg/day). Some studies used up to 2,700 mcg/day for 21 days. The intranasal route provides 92.8% bioavailability and optimal delivery to the CNS. Due to its short plasma half-life (2–3 minutes), multiple daily doses are necessary.

Selank demonstrates nootropic (cognitive-enhancing) properties alongside its anxiolytic effects. Research shows it upregulates BDNF (brain-derived neurotrophic factor), a key protein for learning, memory, and neural plasticity. In one study, Selank protected against ethanol-induced memory impairment by normalizing BDNF levels in the hippocampus and prefrontal cortex. It also modulates serotonin and dopamine, neurotransmitters crucial for mood and cognition.

Selank has an excellent safety profile in clinical studies. It breaks down into natural residues in the body. Unlike benzodiazepines, it causes no sedation, amnesia, cognitive impairment, muscle relaxation, tolerance, or physical dependence. Reported side effects are minimal — occasional mild nasal irritation, transient headaches in the first few days, and vivid dreams early in treatment. No serious adverse events have been reported in published studies.

Research suggests Selank may enhance the effects of benzodiazepines when used together. One study showed that combining Selank with diazepam was more effective at reducing anxiety than either alone, suggesting Selank may increase benzodiazepine receptor affinity. However, drug interactions are not extensively characterized, and combination use should only occur under appropriate research protocols or medical supervision in jurisdictions where it is approved.